MET and non-small cell lung carcinoma: Even though high response rates of MET TKIs in MET amplified and MET exon 14 skipping mutant NSCLC are observed [12–15, 47], acquired resistance is inevitable and the majority of patients with targetable MET aberrations fail to respond to these MET TKIs [17, 48].